Brain 2010 133(8):2281-2294; doi:10.1093/brain/awq101
Stanislava Pankratova1, Darya Kiryushko1, Katrin Sonn2, Vladislav Soroka1, Lene B. Køhler1, Mette Rathje1, Bing Gu1, Kamil Gotfryd1, Ole Clausen1, Alexander Zharkovsky2, Elisabeth Bock1 and Vladimir Berezin1
1 Protein Laboratory, Department of Neuroscience and Pharmacology, University of Copenhagen, 2200 Copenhagen, Denmark 2 Department of Pharmacology, Centre of Excellence for Translational Medicine, University of Tartu, 51014 Tartu, Estonia
Keywords: Erythropoietin, central nervous system, neuroprotective agent, non-haematopoietic erythropoietin, Epotris, neurite outgrowth, blood–brain barrier, neurodegeneration, neurological disorders.
Wednesday, July 28, 2010
Tuesday, July 27, 2010
First causal treatment option for Friedreich's Ataxia via Erythropoietin (EPO)
Technology collaboration OFFER
Abstract
An Austrian university offers the first treatment option for Friedreich´s Ataxia (FRDA), an inherited neurodegenerative disease. It causally targets FRDA
using Erythropoietin (EPO) to increase the level of Frataxin, decreased levels of which are reportedly responsible for the development of FRDA. So far
no other effective treatment is available which is at an advanced development stage. Industrial partners for further developing & commercialising
EPO for the treatment of FRDA are sought.
Date de creation: 23 July 2010
Abstract
An Austrian university offers the first treatment option for Friedreich´s Ataxia (FRDA), an inherited neurodegenerative disease. It causally targets FRDA
using Erythropoietin (EPO) to increase the level of Frataxin, decreased levels of which are reportedly responsible for the development of FRDA. So far
no other effective treatment is available which is at an advanced development stage. Industrial partners for further developing & commercialising
EPO for the treatment of FRDA are sought.
Date de creation: 23 July 2010
Thursday, July 22, 2010
Insulin signaling meets mitochondria in metabolism.
Trends Endocrinol Metab (2010), Published by Elsevier Ltd. DOI: 10.1016/j.tem.2010.06.005
Zhiyong Cheng, Yolanda Tseng and Morris F White
Howard Hughes Medical Institute, Division of Endocrinology, Children's Hospital Boston, Harvard Medical School, Boston MA, USA.
"chronic exposure to high ROS levels could alter mitochondrial function and thereby cause insulin resistance"
Zhiyong Cheng, Yolanda Tseng and Morris F White
Howard Hughes Medical Institute, Division of Endocrinology, Children's Hospital Boston, Harvard Medical School, Boston MA, USA.
"chronic exposure to high ROS levels could alter mitochondrial function and thereby cause insulin resistance"
Tuesday, July 20, 2010
Klinik und Genetik der rezessiven Ataxien -[Clinical details and genetics of recessive ataxias.]
Nervenarzt. 2010 Jul 18. DOI: 10.1007/s00115-010-3079-4
Kühlke C, Kreuz F, Bürk K.
Institut für Humangenetik, Universität zu Lübeck.
[Article in German]
Kühlke C, Kreuz F, Bürk K.
Institut für Humangenetik, Universität zu Lübeck.
[Article in German]
Monday, July 19, 2010
Iron-Sulfur (Fe-S) Cluster Assembly THE SufBCD COMPLEX IS A NEW TYPE OF Fe-S SCAFFOLD WITH A FLAVIN REDOX COFACTOR*
J. Biol. Chem. 2010 285: 23331-23341. First Published on May 11, 2010, doi:10.1074/jbc.M110.127449
Silke Wollers, Gunhild Layer, Ricardo Garcia-Serres, Luca Signor, Martin Clemancey, * Jean-Marc Latour, Marc Fontecave, and Sandrine Ollagnier de Choudens
Silke Wollers, Gunhild Layer, Ricardo Garcia-Serres, Luca Signor, Martin Clemancey, * Jean-Marc Latour, Marc Fontecave, and Sandrine Ollagnier de Choudens
Sunday, July 18, 2010
ArmaGen® Re-engineers Erythropoietin For Brain Penetration
Medical News Today, Article Date: 17 Jul 2010
"EPO drug development for the brain is limited, because EPO does not cross the blood-brain barrier (BBB)"
"EPO-driven neuroprotection in human brain disorders is now possible with systemic administration of the HIRMAb-EPO fusion protein at doses that have minimal effects on erythropoiesis."
ArmaGen® Web
"EPO drug development for the brain is limited, because EPO does not cross the blood-brain barrier (BBB)"
"EPO-driven neuroprotection in human brain disorders is now possible with systemic administration of the HIRMAb-EPO fusion protein at doses that have minimal effects on erythropoiesis."
ArmaGen® Web
Thursday, July 15, 2010
Oxidative stress, thiol redox signaling methods in epigenetics.
Methods Enzymol. 2010; 474: 213-44, doi:10.1016/S0076-6879(10)74013-1
Sundar IK, Caito S, Yao H, Rahman I
Keywords: Epigenetics, gene expression, posttranslational modifications, histones, histone acetylation, deacetylation, methylation, histone acetyltransferases (HATs), histone deacetylases (HDACs), reative oxygen species (ROS), signaling pathways, SIRT1.
Sundar IK, Caito S, Yao H, Rahman I
Keywords: Epigenetics, gene expression, posttranslational modifications, histones, histone acetylation, deacetylation, methylation, histone acetyltransferases (HATs), histone deacetylases (HDACs), reative oxygen species (ROS), signaling pathways, SIRT1.
Tuesday, July 13, 2010
Heterochromatin dysregulation in human diseases
doi:10.1152/japplphysiol.00053.2010
Munich Center for Integrated Protein Science (CiPSM) and Adolf-Butenandt-Institute, Ludwig-Maximilians-University, Munich, Germany
Keywords: epigenetics, heterochromatin, epigenetic therapy, FSHD, Friedreich's ataxia (FRDA), cancer
Sunday, July 11, 2010
The Intermembrane Space of Mitochondria
Antioxidants & Redox Signaling. doi:10.1089/ars.2009.3063.
Johannes M. Herrmann and Jan Riemer
Johannes M. Herrmann and Jan Riemer
Department of Cell Biology, University of Kaiserslautern, Kaiserslautern, Germany.
Saturday, July 10, 2010
Review: Friedreich Ataxia and Erythropoietin
The Open Drug Discovery Journal, Volume 2, ISSN: 1877-3818
Review: Friedreich Ataxia and Erythropoietin, pp.18-24 (7)
Authors: Sylvia Boesch, Brigitte Sturm, Wolfgang Nachbauer, Sascha Hering, Hannes Steinkellner, Rainer Schneider, Werner Poewe, Barbara Scheiber-Mojdehkar
doi: 10.2174/1877381801002020018
FULL TEXT PDF
Review: Friedreich Ataxia and Erythropoietin, pp.18-24 (7)
Authors: Sylvia Boesch, Brigitte Sturm, Wolfgang Nachbauer, Sascha Hering, Hannes Steinkellner, Rainer Schneider, Werner Poewe, Barbara Scheiber-Mojdehkar
doi: 10.2174/1877381801002020018
FULL TEXT PDF
Subscribe to:
Posts (Atom)
